Hightide Therapeutics Inc (HK:2511) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HighTide Therapeutics Inc. has announced a strategic collaboration with SSY Group’s subsidiary, Shijiazhuang No. 4 Pharmaceutical, to advance in the fields of metabolic chronic diseases, longevity, and anti-aging. This partnership aims to combine HighTide’s innovative natural product solutions with SSY’s expertise in pharmaceutical development, potentially leading to groundbreaking advancements in these sectors. Investors are advised to stay informed as the collaboration progresses.
For further insights into HK:2511 stock, check out TipRanks’ Stock Analysis page.